ENGN Stock Soars On Hopeful Data From Bladder Cancer Study
Synopsis
The company is now looking forward to submitting an application for approval of the cancer therapy to the U.S. Food and Drug Administration in the second half of 2026.
Shares of enGene Holdings Inc. (ENGN) jumped 53% in the pre-market session on Tuesday after the company said that its Detalimogene voraplasmid demonstrated a complete response rate of 62% at six months in a study.
The study was evaluating the experimental drug in certain high-risk, Bacillus Calmette-Guérin (BCG)-unresponsive non-muscle invasive bladder cancer (NMIBC) patients.
Complete response rate is the percentage of patients whose cancer disappears completely after treatment, a measure often used in cancer research to evaluate a therapy's effectiveness
The company is now looking forward to submitting an application for approval of the cancer therapy to the U.S. Food and Drug Administration in the second half of 2026.
Get updates to this developing story directly on Stocktwits.<
Stay updated with all the latest Business News, including market trends, Share Market News, stock updates, taxation, IPOs, banking, finance, real estate, savings, and investments. Track daily Gold Price changes, updates on DA Hike, and the latest developments on the 8th Pay Commission. Get in-depth analysis, expert opinions, and real-time updates to make informed financial decisions. Download the Asianet News Official App from the Android Play Store and iPhone App Store to stay ahead in business.